microbeПроблемы особо опасных инфекцийProblems of Particularly Dangerous Infections0370-10692658-719XRussian Research Anti-Plague Institute “Microbe”10.21055/0370-1069-2015-3-104-109microbe-255Research ArticleБИОТЕХНОЛОГИЯ, ИММУНОЛОГИЯBIOTECHNOLOGY, IMMUNOLOGYСовременное состояние разработки вакцин нового поколения против болезни, вызванной вирусом ЭболаCurrent State of the Development of Next-Generation Vaccines against Ebola Virus DiseaseСизиковаТ. Е.SizikovaT. E.noemail@neicon.ruЛебедевВ. Н.LebedevV. N.noemail@neicon.ruБорисевичС. В.BorisevichS. V.noemail@neicon.ruКутаевД. А.KutaevD. A.noemail@neicon.ruБорисевичИ. В.BorisevichI. V.noemail@neicon.ru48 Центральный научно-исследовательский институт Министерства обороныРоссияThe 48th Central Research Institute of the RF Ministry of DefenseRussian FederationНаучный центр экспертизы средств медицинского примененияРоссияScientific Center on Expertise of Medical Application ProductsRussian Federation20152009201503104109Copyright © Сизикова Т.Е., Лебедев В.Н., Борисевич С.В., Кутаев Д.А., Борисевич И.В., 20152015Сизикова Т.Е., Лебедев В.Н., Борисевич С.В., Кутаев Д.А., Борисевич И.В.Sizikova T.E., Lebedev V.N., Borisevich S.V., Kutaev D.A., Borisevich I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.microbe.ru/jour/article/view/255

Представитель рода Ebolavirus семейства Filoviridae вирус Эбола является этиологическим агентом особо опасной вирусной лихорадки, летальность которой достигает 88 %. По мнению ведущих специалистов, вакцинация является наиболее эффективным и экономичным способом защиты от развития эпидемии. Целью данного обзора является анализ современного состояния разработки вакцин нового поколения против болезни, вызванной вирусом Эбола. Установлено, что основными направлениями создания эффективных вакцин против лихорадки Эбола являются разработка вакцин на основе репликонов альфавирусов, вирусподобных частиц, разработка ДНК-вакцин и векторных рекомбинантных вакцин. В обзоре рассмотрены наиболее значимые результаты в направлении создания эффективных средств профилактики в отношении лихорадки Эбола. В настоящее время различными методами получены вакцинные препараты нового поколения, для некоторых из них продемонстрирована высокая защитная эффективность при испытаниях на низших приматах. Наиболее перспективной является векторная рекомбинантная вакцина на основе вируса везикулярного стоматита.

Representative of Ebolavirus gender, Filoviridae family, Ebola virus is an etiological agent of particularly dangerous viral fever, the lethality of which comes up to 88 %. According to the leading specialists and experts in the sphere, vaccination is the most effective and cost-efficient method for the protection from epidemic spread. Objective of the review is to analyze current state of the development of next generation vaccines against Ebola fever. It is established that focus areas of the activities are the construction of vaccines on the basis of alpha-virus replicons, virus-like particles, and the development of DNA-vaccines and vector recombinant vaccines. The paper discusses the most significant achievements in the sphere of obtainment of potent therapies for prophylaxis as regards Ebola fever. To date manufactured, using various approaches, have been the next-generation vaccine preparations, for a number of which high protective capacity is demonstrated in the course of experiments on the nonhuman primates. The most advanced and prospective prototype is the vector recombinant vesicular stomatitis virus-based vaccine.

вирус Эболафиловирусыспецифическая профилактикавекторные рекомбинантные вакциныДНК-вакцинывирусподобные частицыРНК-репликоныаденовирусвирус везикулярного стоматитаEbola virushemorrhagic feverfilovirusesspecific prophylaxisvector recombinant vaccinesDNA-vaccinesvirus-like particlesRNA-repliconsadenovirusvesicular stomatitis virusReferencesDowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., Paragas J., Hogan R.J., Schmaljohn C. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J. Virol. 2007; 81(4):1821-37.Dowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., Paragas J., Hogan R.J., Schmaljohn C. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J. Virol. 2007; 81(4):1821–37.Emond R.T. Viral hemorrhagic fevers. J. Infect. 1986; 13:103-6.Emond R.T. Viral hemorrhagic fevers. J. Infect. 1986; 13:103–6.Feldmann H., Geisbert T.W. Ebola hemorrhagic fever. Lancet. 2011; 377:849-62.Feldmann H., Geisbert T.W. Ebola hemorrhagic fever. Lancet. 2011; 377:849–62.Feldmann H., Jones S., Klenk H.D., Schnittler H.J. Ebola virus: From discovery to vaccine. Nat. Rev. Immunol. 2003; 3:677-85.Feldmann H., Jones S., Klenk H.D., Schnittler H.J. Ebola virus: From discovery to vaccine. Nat. Rev. Immunol. 2003; 3:677–85.Geisbert T.W., Daddario-DiCaprio K.M., Geisbert J.B., Reed D.S., Feldmann F., Grolla A., Stroher U., Fritz E.A., Hensley L.E., Jones S.M., Feldmann H. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26:6894-900.Geisbert T.W., Daddario-DiCaprio K.M., Geisbert J.B., Reed D.S., Feldmann F., Grolla A., Stroher U., Fritz E.A., Hensley L.E., Jones S.M., Feldmann H. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26:6894–900.Geisbert T.W., Daddario-DiCaprio K.M., Lewis M.G., Geisbert J.B., Grolla A., Leung A., Paragas J., Matthias L., Smith M.A., Jones S.M., Hensley L.E., Feldmann H., Jahrling P.B. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008; 4(11):1-9.Geisbert T.W., Daddario-DiCaprio K.M., Lewis M.G., Geisbert J.B., Grolla A., Leung A., Paragas J., Matthias L., Smith M.A., Jones S.M., Hensley L.E., Feldmann H., Jahrling P.B. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008; 4(11):1–9.Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J.N., Geisbert J.B., Leung A., Feldmann F., Hensley L.E., Feldmann H., Jones S.M. Recombinant vesicular stomatitis virus vector mediaters postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 2008; 82(11):5664-8.Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J.N., Geisbert J.B., Leung A., Feldmann F., Hensley L.E., Feldmann H., Jones S.M. Recombinant vesicular stomatitis virus vector mediaters postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 2008; 82(11):5664–8.Geisbert T.W., Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 2011; 204(3):1075-81.Geisbert T.W., Feldmann H. Recombinant vesicular stomatitis virusbased vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 2011; 204(3):1075–81.Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., Feldmann H. Single-Injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 2009; 83(14):7296-304.Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., Feldmann H. Single-Injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 2009; 83(14):7296–304.Kiley M.P., Bowen E.T., Eddy G.A., Isaacson M., Johnson K.M., McCormick J.B., Murphy F.A., Pattyn S.R., Peters D., Prozesky O.W., Regnery R.L., Simpson D.I.H., Slenczka W., Sureau P. van der Groen G., Webb P.A., Wulff H. Filoviridae: A taxonomic home for Marburg and Ebola viruses? Intervirology. 1982; 18:24-32.Kiley M.P., Bowen E.T., Eddy G.A., Isaacson M., Johnson K.M., McCormick J.B., Murphy F.A., Pattyn S.R., Peters D., Prozesky O.W., Regnery R.L., Simpson D.I.H., Slenczka W., Sureau P. van der Groen G., Webb P.A., Wulff H. Filoviridae: A taxonomic home for Marburg and Ebola viruses? Intervirology. 1982; 18:24–32.Kobinger G.P., Croyle M., Feldmann H. Ebola and Marburg. Vaccines for Biodefense and Emerging and Neglected Diseases. London (UK): Academic Press; 2009. P. 25-37.Kobinger G.P., Croyle M., Feldmann H. Ebola and Marburg. Vaccines for Biodefense and Emerging and Neglected Diseases. London (UK): Academic Press; 2009. P. 25–37.Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., Jones S., Wilson J.M. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. J. Virol. 2006; 346:394-401.Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., Jones S., Wilson J.M. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. J. Virol. 2006; 346:394–401.Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S., Smith L.A., Smith J.F. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice Vaccine. 2006; 24:6886-92.Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S., Smith L.A., Smith J.F. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice Vaccine. 2006; 24:6886–92.Lesley C.D., Schmaljohn C.S. DNA vaccines for biodefense. Expert Rev. Vaccines. 2009; 8:739-54.Lesley C.D., Schmaljohn C.S. DNA vaccines for biodefense. Expert Rev. Vaccines. 2009; 8:739–54.Lundstrom K. Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines. 2003; 2:447-59.Lundstrom K. Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines. 2003; 2:447–59.MDPI Viruses [Internet]. Special Issue “Advances in Filovirus Research 2012” [cited 23 March 2015]. Available from: http://www.mdpi.com/journal/viruses/special_issues/Filovirus.MDPI Viruses [Internet]. Special Issue “Advances in Filovirus Research 2012” [cited 23 March 2015]. Available from: http://www.mdpi.com/journal/viruses/special_issues/Filovirus.Mire C.E., Geisbert J.B., Marzi A., Agans K.N., Feldmann H., Geisbert T.W. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl. Trop. Dis. 2013; 7(12):1-11.Mire C.E., Geisbert J.B., Marzi A., Agans K.N., Feldmann H., Geisbert T.W. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl. Trop. Dis. 2013; 7(12):1–11.Nabel C., Yang Z., Sulliva N., Sanches A. Development of a preventive vaccine for filovirus infection in primates. Patent US 8.124 592 B2 2012.Nabel C., Yang Z., Sulliva N., Sanches A. Development of a preventive vaccine for filovirus infection in primates. Patent US 8.124 592 B2 2012.Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003; 11:438-44.Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003; 11:438–44.Potential use of live viral and bacterial vectors for vaccines. WHO meeting, Geneva, 19-22 June, 1989. Vaccine. 1990; 8(5):425-37.Potential use of live viral and bacterial vectors for vaccines. WHO meeting, Geneva, 19–22 June, 1989. Vaccine. 1990; 8(5):425–37.Pushko P., Geisbert J., Parker M., Jahrling P.B., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against lnfection with Lassa and Ebola viruses. J. Virol. 2001; 75:11677-85.Pushko P., Geisbert J., Parker M., Jahrling P.B., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against lnfection with Lassa and Ebola viruses. J. Virol. 2001; 75:11677–85.Radoshitzky S.R., Kuhn J.H., de Kok-Mercado F., Jahrling P.B., Bavari S. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin. Drug Discov. 2012; 7(7):613-32.Radoshitzky S.R., Kuhn J.H., de Kok-Mercado F., Jahrling P.B., Bavari S. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin. Drug Discov. 2012; 7(7):613–32.Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 2002; 12:279-96.Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 2002; 12:279–96.Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola Viruses. Fields virology. Philadelphia, PA, USA: Lippincott Williams and Wilkins; 2007. P. 1279-304.Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola Viruses. Fields virology. Philadelphia, PA, USA: Lippincott Williams and Wilkins; 2007. P. 1279–304.Seregin A.V., Yun N.E., Poussard A.L., Peng B.-H., Smith J.F., Smith J.N., Milagros S., Paessler S. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine. 2010; 28:4713-8.Seregin A.V., Yun N.E., Poussard A.L., Peng B.-H., Smith J.F., Smith J.N., Milagros S., Paessler S. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine. 2010; 28:4713–8.Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H.H.V., Popernack P.M., Yang Z.Y., Pau M.G., Roederer M., Koup R.A., Goudsmit J., Jahrling P.B., Nabel G.J. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Medicine. 2006; 3(6):865-73.Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H.H.V., Popernack P.M., Yang Z.Y., Pau M.G., Roederer M., Koup R.A., Goudsmit J., Jahrling P.B., Nabel G.J. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Medicine. 2006; 3(6):865–73.Swenson D.L., Wang D., Luo M., Warfield K.L., Woraratanadharm J., Holman D.H., Dong J.Y., Pratt W.D. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. J. Clin. Vaccine Immunol. 2008;15(3):460-7.Swenson D.L., Wang D., Luo M., Warfield K.L., Woraratanadharm J., Holman D.H., Dong J.Y., Pratt W.D. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. J. Clin. Vaccine Immunol. 2008;15(3):460–7.Wang D., Raja N.U., Trubey C.M., Juompan L.Y., Luo M., Woraratanadharm J., Deitz S.B., Yu.H., Swain B.M., Moore K.M., Pratt W.D., Hart M.K., Dong J.Y. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 2006; 80(6):2738-46.Wang D., Raja N.U., Trubey C.M., Juompan L.Y., Luo M., Woraratanadharm J., Deitz S.B., Yu.H., Swain B.M., Moore K.M., Pratt W.D., Hart M.K., Dong J.Y. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 2006; 80(6):2738–46.Warfield K.L., Bosio C.M., Welcher B.C. Ebola virus-like particles protect from lethal Ebola virus infection. J. Immunol. 2005; 175:1184-91.Warfield K.L., Bosio C.M., Welcher B.C. Ebola virus-like particles protect from lethal Ebola virus infection. J. Immunol. 2005; 175:1184–91.Warfield K.L., Javad M.A. Advances in virus-like particle vaccines for filoviruses. J. Infect. Dis. 2011; 204(3):1053-59.Warfield K.L., Javad M.A. Advances in virus-like particle vaccines for filoviruses. J. Infect. Dis. 2011; 204(3):1053–59.Warfield K.L., Swenson D.L, Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 2007; 196(2):430-7.Warfield K.L., Swenson D.L, Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 2007; 196(2):430–7.Warfield K.L., Swenson G.G., Demmin G., Bavari S. Filovirus-like particle as vaccines and discovery tools. Expert Rev. Vaccines. 2005; 4:429-40.Warfield K.L., Swenson G.G., Demmin G., Bavari S. Filovirus-like particle as vaccines and discovery tools. Expert Rev. Vaccines. 2005; 4:429–40.

The authors declare that there are no conflicts of interest present.